| --- | --- | --- | --- | --- | --- | |-----------------------|-------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investor Presentation | NeoGenomics | | | | | | April 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy s ...

Financial Performance - Consolidated revenue increased by 9.0% compared to 2020, with Clinical Services revenue up by 5.7% and Pharma Services revenue up by 29.1%[227] - Total net revenue increased by $39.9 million, or 9.0%, from $444.4 million in 2020 to $484.3 million in 2021[258] - Clinical Services revenue rose by $21.8 million, or 5.7%, to $404.2 million in 2021, despite exiting COVID-19 PCR testing[258][259] - Pharma Services revenue increased by $18.0 million, or 29.1%, to $80.2 million in 2021, driven by research studies and informatics[260] - The net loss for 2021 was $8.3 million, compared to a net income of $4.2 million in 2020[323] - Basic net loss per share was $0.07, down from a net income per share of $0.04 in the previous year[323] - Total assets increased to $1.87 billion in 2021, up from $988.3 million in 2020, reflecting a growth of 89.3%[321] - Total liabilities also rose to $761.5 million, compared to $294.0 million in 2020, marking an increase of 158.5%[321] - Stockholders' equity increased to $1.11 billion in 2021, up from $694.3 million in 2020, representing a growth of 60.0%[321] Expenses and Costs - Gross profit margin decreased from 41.8% in 2020 to 38.6% in 2021, primarily due to amortization of acquired technology intangibles[264] - General and administrative expenses surged by $77.6 million, or 53.9%, to $221.3 million in 2021, reflecting acquisition costs and increased personnel[266] - Research and development expenses increased significantly by $13.6 million, or 165.8%, to $21.9 million in 2021, focusing on new test development[268] - Sales and marketing expenses rose by $14.7 million, or 30.8%, to $62.6 million in 2021, attributed to higher commissions and expanded sales team[270] - Cost of revenue increased by 15.0% to $297.3 million in 2021, influenced by higher payroll and amortization costs[263] Cash Flow and Financing - Cash used in operating activities was $26.7 million in 2021, which included $15.7 million of acquisition and integration costs and $53.4 million in depreciation and amortization[281] - Cash used in investing activities increased to $632.4 million in 2021, primarily due to $419.4 million for acquisitions and $133.8 million in marketable securities[283] - Cash provided by financing activities was $725.3 million in 2021, significantly higher than $235.6 million in 2020, driven by $408.1 million from equity offerings and $334.4 million from convertible debt[284] - The company had $316.8 million in cash and cash equivalents and $198.6 million in marketable securities as of December 31, 2021, sufficient to support operational liquidity needs for at least the next 12 months[285] Acquisitions and Investments - Acquired Trapelo and Inivata, adding liquid biopsy platform technology and MRD testing capabilities to the oncology testing portfolio[227] - The acquisition of Inivata Limited was completed on June 18, 2021, with a business enterprise value of $552.8 million and a Purchase Option recorded at fair value of $74.3 million[311] - The acquisition of Trapelo Health on April 7, 2021, involved a total purchase consideration of $64.8 million, including cash of $35.6 million and equity valued at $29.2 million[406] - The estimated goodwill from the Trapelo acquisition is approximately $44.7 million, primarily due to expected synergies and the acquisition of an assembled workforce[409] - The Company recorded a gain of $109.3 million for the year ended December 31, 2021, related to the acquisition of Inivata, including a measurement period adjustment of $17.8 million[415] Operational Developments - Transitioned the majority of testing in Fort Myers to a new headquarters and laboratory facility, enhancing capacity for future growth[227] - Plans to expand test offerings, including advanced NGS tools, and continue global expansion in Europe and Asia[224] - Focus on developing informatics and data-related tools to assist stakeholders in identifying patients for clinical trials[225] - Aims to drive down testing costs through investments in information technology and automation[226] Regulatory and Compliance - The company is committed to providing transparency and choice to patients regarding their data handling and use[241] - The company reported a reserve of $11.2 million in long-term liabilities related to a regulatory matter concerning compliance with federal healthcare laws[316] - The financial statements were audited and presented fairly in all material respects as of December 31, 2021, in accordance with U.S. GAAP[302] Market and Economic Factors - The company has operations in multiple countries, exposing it to foreign currency exchange risks, but does not currently hedge these risks[297] - Inflation has not materially affected the business in the past, but ongoing inflationary pressures could negatively impact future financial results[294] - The company does not expect a significant change in its uncertain tax positions related to Federal and State R&D tax credits in the next 12 months[396]

Company Overview - NeoGenomics' total revenue for FY 2021 was $484 million, with a year-over-year growth of 16%[8] - The company performed 1,086,768 core clinical tests in FY 2021[8] - Clinical services accounted for 83% of FY 2021 revenue, while pharma services/informatics contributed 17%[8] - As of December 31, 2021, the company had signed contracts worth over $265 million in backlog for Pharma Services[9] Market and Growth Drivers - The oncology testing market is estimated to grow at an annual rate of 6% to 8%[12] - The number of cancer survivors is projected to increase by 31.4% to 22.2 million by 2030, driving increased testing[14] - The late-phase oncology pipeline increased 100% from 2008 to 2018, with diagnostic testing being critical as additional drugs gain approval[20] Financial Performance (Q4 2021) - Clinical revenue for Q4 2021 was $104.053 million, a decrease of 2.5% compared to Q4 2020 ($106.738 million)[65] - Pharma revenue for Q4 2021 was $21.679 million, an increase of 12.6% compared to Q4 2020 ($19.259 million)[65] - The company recorded $48 million in new signed contracts for Pharma Services in Q4 2021[42] - Adjusted EBITDA for the year ended December 31, 2021, was a loss of $(4,161) thousand, compared to a profit of $34,842 thousand in 2020[70]

NeoGenomics Inc. (NASDAQ:NEO) Q4 2021 Earnings Conference Call February 23, 2022 8:30 AM ET Company Participants Mark Mallon - Chief Executive Officer William Bonello - Chief Financial Officer Clive Morris - President, Inivata George Cardoza - President, Chief Operating Officer Gina Waller - President, Pharma Services Clynt Taylor - President, Informatics Charlie Eidson - Director, Investor Relations Conference Call Participants Brian Weinstein - William Blair Mark Massaro - BTIG Alex Nowak - Craig Hallum P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpora ...

NeoGenomics Conference Call Prepared Remarks Good morning. I'd like to welcome everyone to NeoGenomics' 2021 Third Quarter conference call. Joining me for this call from our new headquarters in Fort Myers are George Cardoza, President and Chief Operating Officer of our Lab Operations, Doug Brown, our Chief Strategy and Corporate Development Officer and Charlie Eidson, our Director of Investor Relations. Joining on the call via phone from California is Dr. Gina Wallar, President of our Pharma Services Divisi ...

Financial Data and Key Metrics Changes - Company revenue increased by 12% year-over-year to $121 million in Q3 2021, excluding discontinued COVID-19 PCR testing revenue [14][38] - Clinical revenues grew 11% year-over-year to $102 million, driven by a 7% increase in clinical volume and a 4% increase in revenue per test [38] - Adjusted EBITDA was a loss of $3 million in Q3, reflecting lower than anticipated revenues and expenses from recent acquisitions [47] Business Line Data and Key Metrics Changes - Pharma Services revenue grew 14% year-over-year to $19 million, with a year-to-date growth rate of 36% [42][43] - Pharma Services bookings increased by 41% year-over-year, reaching an all-time high of $49 million, with a record backlog of $261 million [16][43] Market Data and Key Metrics Changes - The company was significantly impacted by the Delta variant, particularly in Florida and Texas, which together represent over 20% of total revenue [39][40] - Daily volume trends in Florida were approximately 5% below previous lows, contrasting with a 9% increase in other sales regions nationwide [41] Company Strategy and Development Direction - The company presented a five-year growth plan to the Board, focusing on strengthening leadership in oncology diagnostics and launching the RaDaR assay for minimal residual disease testing [17][18] - Plans to double the customer-facing sales force and expand Precision Medicine teams to accelerate growth and market penetration [19][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, expecting higher rates of growth in core Clinical business and Pharma Services as COVID-19 cases decline [16] - The company is committed to investing in the RaDaR assay, anticipating it will significantly increase long-term growth rates [18][57] Other Important Information - The company is undergoing an internal investigation related to compliance with federal healthcare laws, with a reserve of $10.5 million accrued for potential damages [49][50] - The company is lowering its annual revenue guidance to a range of $482.5 million to $487.5 million due to the impact of the Delta variant [51][52] Q&A Session Summary Question: Can you provide insights on the EBITDA guidance and its trajectory? - Management indicated that limited access for the sales team in Q3 will impact Q4 topline, but investments in the sales team will begin to reflect in Q4 [63][65] Question: How do you view the competitive landscape in NGS and liquid biopsy? - Management emphasized their established relationships with community hospitals and oncologists as a competitive advantage, alongside their commitment to lead in the MRD market with RaDaR [79][80] Question: What is the expected timeline for the RaDaR assay's reimbursement? - Management is confident in their reimbursement strategy and plans to submit for initial reimbursement around the turn of the year [87][110] Question: Can you elaborate on the backlog in Pharma Services? - The backlog generally converts over an average of three years, with 60% to 80% of contracts expected to come through [102] Question: How will the company differentiate itself in the crowded MRD market? - Management highlighted their potentially class-leading sensitivity and established channels to customers as key differentiators [128][130]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q2 2021 Earnings Conference Call August 6, 2021 8:30 AM ET Company Participants Doug VanOort - Chairman Mark Mallon - CEO Kathryn McKenzie - CFO George Cardoza - President, Pharma Services Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy and Corporate Development Officer Clive Morris - CEO, Inivata Conference Call Participants David Westenberg - Guggenheim Brian Weinstein - William Blair Alex Nowak - Craig-Hallum Capital Group Mark Massaro - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporatio ...